Literature DB >> 11264037

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.

K Bush1.   

Abstract

Of the 340 discrete beta-lactamases that have been identified, the most important groups of enzymes that are continuing to proliferate include the plasmid-encoded cephalosporinases, the metallo-beta-lactamases, and the extended-spectrum beta-lactamases. Resistance to specific beta-lactam-containing antimicrobial agents frequently can be traced to a single beta-lactamase, but this task is becoming more difficult for the clinical microbiology laboratory. Other factors, such as multiple beta-lactamase production, transferable multidrug-resistance genes, alterations in outer-membrane porins, and possible antibiotic efflux, all may contribute to a resistance phenotype. Appreciation of these factors may help the physician make a more informed decision when choosing therapy to try to avoid selection of even more pathogenic strains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264037     DOI: 10.1086/319610

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  113 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  In vitro and in vivo activities of AM-112, a novel oxapenem.

Authors:  Conor E Jamieson; Peter A Lambert; Iain N Simpson
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 3.  Recent developments in beta lactamases and extended spectrum beta lactamases.

Authors:  Joumana N Samaha-Kfoury; George F Araj
Journal:  BMJ       Date:  2003-11-22

4.  Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem.

Authors:  Laurent Poirel; Claire Héritier; Isabelle Podglajen; Wladimir Sougakoff; Laurent Gutmann; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 6.  Bacterial wall as target for attack: past, present, and future research.

Authors:  Arthur L Koch
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

7.  In vivo acquisition of high-level resistance to imipenem in Escherichia coli.

Authors:  Laurent Poirel; Claire Héritier; Colette Spicq; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

8.  Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate.

Authors:  Francisco José Pérez-Llarena; Ana Fernández; Laura Zamorano; Frédéric Kerff; Alejandro Beceiro; Belén Aracil; Emilia Cercenado; Elisenda Miro; Antonio Oliver; Jesús Oteo; Ferran Navarro; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2012-06-05       Impact factor: 5.191

9.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

Review 10.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.